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We analysed key biochemical features that reflect the balance
between glycolysis and glucose oxidation in cybrids (cytoplasmic
hybrids) harbouring a representative sample of mitochondrial
DNA point mutations and deletions. The cybrids analysed had the
same 143B cell nuclear background and were isogenic for the mi-
tochondrial background. The 143B cell line and its ρ0 counterpart
were used as controls. All cells analysed were in a dynamic state,
and cell number, time of plating, culture medium, extracellular
volume and time of harvest and assay were strictly controlled.
Intra- and extra-cellular lactate and pyruvate levels were measured
in homoplasmic wild-type and mutant cells, and correlated with
rates of ATP synthesis and O2 consumption. In all mutant cell
lines, except those with the T8993C mutation in the ATPase
6 gene, glycolysis was increased even under conditions of low
glucose, as demonstrated by increased levels of extracellular
lactate and pyruvate. Extracellular lactate levels were strictly and
inversely correlated with rates of ATP synthesis and O2 consump-
tion. These results show increased glycolysis and defective
oxidative phosphorylation, irrespective of the type or site of the
point mutation or deletion in the mitochondrial genome. The dif-
ferent biochemical consequences of the T8993C mutation suggest
a uniquely different pathogenic mechanism for this mutation.
However, the distinct clinical features associated with some of
these mutations still remain to be elucidated.
Key words: ATP synthesis, cybrid, lactate, mitochondrial DNA
mutation, oxygen consumption, pyruvate.
INTRODUCTION
Mitochondria are the main source of cellular ATP, which is
generated by the transfer of electrons along complexes I to IV of
the mitochondrial respiratory chain and by the phosphorylation
of ADP by complex V (ATP synthase) [1]. In addition to the
nuclear genome, cells contain mtDNA (mitochondrial DNA), a
double-stranded circular molecule present in multiple copies in
each mitochondrion, which encodes for 22 tRNAs, 13 poly-
peptides and two rRNAs. All 13 polypeptides are components of
the respiratory chain. Mutations in the mitochondrial genome have
been described in a heterogeneous group of disorders in which
the nervous system and skeletal muscle are predominantly, but not
exclusively, affected (mitochondrial encephalomyopathies). The
main biochemical consequences of pathogenic mtDNA mutations
are impaired respiratory capacity and ATP synthesis. Since the
oxidative phosphorylation system is controlled by both genomes,
genetic mitochondrial diseases can be sporadic, transmitted by
Mendelian inheritance (nuclear DNA mutations) or by maternal
inheritance (mtDNA mutations). Point mutations in rRNA, tRNA
and polypeptide-coding genes are usually maternally inherited,
whereas large-scale rearrangements of mtDNA are usually
sporadic [2].
The diagnosis of mitochondrial diseases is based on morpho-
logical, biochemical and molecular genetic analyses of muscle.
Because it is often difficult to obtain enough material to study
pathogenic mechanisms, patient-derived cell culture models have
been used to establish bioenergetic deficits and to analyse bio-
chemical phenotypes. Even though primary cultures of skin or
muscle are appropriate for biochemical and molecular genetic
analyses, mtDNA heteroplasmy [i.e. the co-existence of M
(mutant) and WT (wild-type) genomes in the same cell] and sen-
escence on prolonged passaging limit their usefulness. Lympho-
blastoid cell lines have been useful, but heteroplasmy remains a
problem [3]. The cell culture model most extensively used for
the study of mitochondrial disorders is the cybrid (cytoplasmic
hybrid) system, which was first described in mammalian cells
by King and Attardi [4]. Cybrids are generated by fusion of
enucleated cytoplasts from patients’ cells harbouring mtDNA
mutations with cells lacking mtDNA (ρ0), grown under selection
and subcloned. This technique permits the analysis of cell lines
that are isogenic for mtDNA, have a neutral nuclear background
and contain not only homoplasmic WT and homoplasmic M
mtDNA, but also cells with different percentages of M molecules
from the same patient. Several mtDNA mutations have been
studied and characterized using this system [5].
Most point mutations studied by this method are in the tRNA
genes. Mutations in the tRNALeu (UUR) gene are found in patients
with MELAS (mitochondrial encephalomyopathy with lactic
acidosis and stroke-like episodes). Cybrids with mutations at
nt 3243 and 3271 had decreased complex I activity and defective
protein synthesis, resulting in respiratory chain dysfunction [6],
although the T3271C mutation was associated with a milder
biochemical phenotype [7]. Patients with MERRF (myoclonus
Abbreviations used: cybrid, cytoplasmic hybrid; DMEM, Dulbecco’s modified Eagle’s medium; EC, extracellular; IC, intracellular; L/P, lactate-to-pyruvate
ratio; M, mutant; MELAS, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; MERRF, myoclonus epilepsy with ragged-red
fibres; NARP/MILS, neuropathy, ataxia, retinitis pigmentosa/maternal inherited Leigh’s syndromes; MIDD, maternally inherited diabetes and deafness;
mtDNA, mitochondrial DNA; TCA, trichloracetic acid; WT, wild-type.
1 To whom correspondence should be addressed (email mmd2@columbia.edu).
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epilepsy with ragged-red fibres) have point mutations in the
tRNALys gene. Cybrids harbouring the two most frequent MERRF
mutations (A8344G and T8356C) show severe reduction in
protein synthesis, synthesis of aberrant translation products and
defective amino-acylation of the tRNA [8]. Two transitions at the
same nucleotide of the ATPase 6 gene (T8993G and T8993C) are
associated with the NARP/MILS (neuropathy, ataxia, retinitis
pigmentosa/maternal inherited Leigh’s syndromes) clinical phen-
otypes [9,10]. Cybrids homoplasmic for the T8993G mutation
showed a residual ATP synthesis capacity of 20% to 35%
[11,12]. Cybrids harbouring large-scale mtDNA deletions also
had impaired protein synthesis, probably due to the ablation of
one or more tRNA genes [13], and resulted in severe respiratory
chain deficiency [14,15].
Since mtDNA mutations cause a wide spectrum of clinical and
biochemical phenotypes, any understanding of pathogenesis re-
quires that multiple aspects of bioenergetics be analysed in culture
models. These include: (i) the end-point of glycolysis at the level
of lactate and pyruvate, (ii) the terminal step of oxidative phospho-
rylation, resulting in ATP synthesis, and (iii) overall respiratory
chain function, as reflected by rates of O2 consumption.
Rates of ATP synthesis varied widely in studies of cell lines
using different methods [11,16–20], and a few studies of M
cybrids reported defective O2 consumption [6,8], but neither the
rates of ATP synthesis nor the rates of O2 consumption were
correlated with rates of glycolysis or glucose oxidation. Therefore,
there is no comprehensive picture of the metabolic profile in cells
harbouring mtDNA mutations.
In the present study, we have analysed key biochemical features
that reflect the global bioenergetic status of cybrid cell lines har-
bouring a representative sample of point mutations and rearrange-
ments. We have measured intra- and extra-cellular lactate and pyr-
uvate in homoplasmic WT and homoplasmic M cybrids, and we
have correlated these levels with ATP synthesis and the rate of O2
consumption. Both WT and M cybrids had the same 143B cell
nuclear background and were isogenic in terms of mitochondrial
background (i.e. both WT and M mitochondria came from the
same patient). All cells studied were in a dynamic state, where cell
number, time of plating, culture components, EC (extracellular)
volume, time of harvest and assay were strictly controlled. Our
results revealed that all mutations, except for T8993C, increased
glycolysis even under conditions of low glucose, as demonstrated
by increased EC lactate and pyruvate. We also observed good
correlations between EC lactate, mitochondrial ATP synthesis
and rates of O2 consumption.
EXPERIMENTAL
Cybrid cell lines and cell culture
The cybrid cell lines used in this study have been described
in previous publications (Table 1) [6–11,21–26]. We selected
homoplasmic WT and homoplasmic M cell lines for each mut-
ation after RFLP (restriction-fragment-length polymorphism)
analysis (point mutations) or Southern blot analysis (deletions).
For analysis of ATP synthesis, 1 × 106 cells were plated in 10 ml
of DMEM (Dulbecco’s modified Eagle’s medium) containing
2 mg/ml glucose, 2.5 mg/ml galactose and 110 µg/ml pyruvate,
and were supplemented with 50 µg/ml uridine and 10% fetal
bovine serum. Cells growing exponentially in 10 cm2 dishes were
harvested at 70–80% confluency and analysed the same day.
For lactate and pyruvate assays, 6 × 105 cells were plated in
6 cm2 dishes in 5 ml of regular DMEM containing 4.5 mg/ml glu-
cose. After 24 h, the medium was changed to DMEM containing
2 mg/ml glucose, 2.5 mg/ml galactose and 110 µg/ml pyruvate,
Table 1 Homoplasmic cybrid cell lines analysed
FLP, WS, RN, MM, LB, KB, JCP, DMP, AT and CW refer to patients’ cell lines.
Mutation Source of
Mutation reference Cybrids used Cybrids reference mitochondria
MELAS A3243G [22] WS 241 (WT) [6] Fibroblasts
WS 176 (M)
RN 236 (WT) Myoblasts
RN 164 (M)
MELAS T3271C [23] MM 71 (WT) [7] Fibroblasts
MM 37 (M)
MM 63 (M)
MERRF A8344G [25] LB 18 (WT) [8] Fibroblasts
LB 172 (WT)
LB 12 (M)
LB 64 (M)
MERRF T8356C [26] KB 30 (WT)
KB 42 (M) [8] Fibroblasts
KB 57 (M)
KB 106 (M)
NARP T8993G [9] JCP 213 (WT) [11] Platelets
JCP 261 (M)
JCP 239/Eb13-13
NARP T8993C [10] DMP 20/Eb10-21(WT) Pers.Com. Platelets
DMP 20/Eb10-3 (M)
DMP 20/Eb 10-22 (M)
AT 153 (WT) Unpublished work† Fibroblasts
AT 101 (M)
Deletions [24] [21]
FLP‡ FLP 6a39.2 (WT) Fibroblasts
FLP 6a39.32 (M)
CW§ CW 440-116 (WT) Fibroblasts
CW 420-106 (WT)
CW 420-115 (M)
* G. Manfredi, personal communication.
† M. Davidson and M. P. King.
‡  1.9 kb, nt 7846–9748.
§  5.8 kb, nt 10 155–15 945.
supplemented with 50 µg/ml uridine and 10% fetal bovine serum.
After 48 h in low glucose, the cells were harvested and counted,
and lactate and pyruvate levels were measured in the cell pellet
(intracellular, IC) and in the medium (EC).
IC and EC lactate and pyruvate measurements
The cell pellet was washed in cold PBS, resuspended in one
volume of cold PBS, sonicated with three 15-s pulses, and depro-
teinized with 3 vol. of 10% TCA (trichloracetic acid). The
medium was deproteinized with 4 vol. of 10% TCA. The TCA
precipitates from the cell pellet and from the medium were vortex-
mixed, left to stand in ice for 5 min and centrifuged. Then the
supernatants were used for the assay.
Lactate levels were measured in 0.1 ml of the supernatant
spectrophotometrically using the lactate kit UV 826 (Sigma.,
St. Louis, MO, U.S.A.), together with appropriate blanks con-
taining 0.1 ml of 10% TCA, and standards (metabolite control,
Sigma). IC lactate levels were expressed as µmol of lactate per
106 cells. Because cell counts at harvest varied from dish to dish,
EC lactate levels in the total volume of the medium (5 ml) were re-
ferred to cell counts and expressed as mmol of lactate in medium/
106 cells, thus keeping the units of IC and EC lactates uniform.
Pyruvate levels were analysed in 0.25 ml of TCA-treated
supernatant from cells (IC) and 0.5 ml of TCA-treated supernatant
from medium (EC). The change in absorbance at 340 nm at
c© 2004 Biochemical Society
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37 ◦C in the presence of NADH and LDH was measured in a
Cary UV100 spectrophotometer (Varian Inc., Walnut Creek, CA,
U.S.A.) using a pyruvate kit UV-726 (Sigma). IC and EC pyruvate
levels were calculated and expressed as above.
ATP synthesis
The rate of ATP synthesis was assayed by incubating cells (5 ×
106/ml) permeabilized by digitonin [27], with 20 mM succinate
plus 4 µM rotenone. The reaction, started by addition of 0.5 mM
ADP, was stopped after 5 min at 30 ◦C by addition of about 80%
DMSO. The ATP content was measured by the luciferin–lucifer-
ase chemiluminescent method [28], and oligomycin sensitivity
was determined by pre-incubating the sample with 15 µM
oligomycin.
O2 consumption
Homoplasmic WT and M cybrids harbouring the different mtDNA
mutations, 143B (ρ+) and 143B206 (ρ0) cells (controls), cultured
in 10 cm2 dishes as described above, were treated with trypsin at
exponential phase. Aliquots of 5 × 106 cells were resuspended in
1.5 ml of DMEM without glucose, supplemented with pyruvate,
and the rate of O2 consumption of whole cells was recorded
for 3 min using a Clark O2 electrode (Hansatech Instruments,
King’s Lynn, Norfolk, U.K.). All measurements were carried out
in triplicate at two different time points.
Citrate synthase
Citrate synthase was assayed in freshly harvested cells by the
method of Sre`re [29]. Cells were resuspended in PBS, lysed by
two freeze–thaw cycles, incubated with DTNB [5,5′-dithiobis-
(2-nitrobenzoic acid)], acetyl-CoA and oxaloacetate, and the
change in absorbance at 412 nm was recorded in a Cary UV100
spectrophotometer. The enzyme activities were normalized to mg
of protein in the cell lysate.
RESULTS AND DISCUSSION
The major function of mitochondria is to synthesize ATP from
ADP and Pi through the action of the F1Fo-ATP synthase, which
transduces the electrochemical gradient energy derived from the
oxidation of NADH and FADH2 in the respiratory chain [30].
Therefore, mutations in mtDNA, which encodes the 13 polypep-
tides of the respiratory chain, are expected to impair energy
metabolism. To test this hypothesis, we analysed cybrids with
the 143B nuclear background and harbouring the most frequent
pathogenic mtDNA point mutations and rearrangements. We com-
pared energy metabolism intermediates and respiratory function
in cells repopulated with either homoplasmic WT or M mtDNA
molecules from the same patient. The cells analysed were
therefore isogenic with respect to both nuclear and mitochondrial
genome. We have used the parental 143B cells as WT (ρ+) con-
trols and the ρ0 derivative, 143B206 cells, as negative controls.
Cybrid cells are normally grown in medium containing high
glucose (4.5 mg/ml). To reveal subtle biochemical defects while
maintaining normal cell functions during the period of study,
the cells were maintained in medium containing only 2 mg/ml
glucose, but supplemented with 2.5 mg/ml galactose as a carbon
source for biosynthetic functions. We performed our studies 48 h
after fluid change, thus allowing us to examine the products of gly-
colysis in both the IC and EC compartment at peak growth phase.
The results of the biochemical analyses in cybrids harbouring
0 and 100%M mtDNA, and in ρ0 and ρ+ controls, are presented
in Figures 1 and 2, and Tables 2 and 3. The data revealed a
Figure 1 Correlation between EC lactate and O2 consumption in cybrids
with homoplasmic WT and homoplasmic mtDNA mutations
Figure 2 Correlation between ATP synthesis and O2 consumption in cybrids
with homoplasmic WT and homoplasmic mtDNA mutations
wide variation in EC lactate concentration, O2 consumption and
ATP synthesis, among the different WT cybrids analysed. This
variation, which had been noted by King and Attardi [4] in their
original report, is probably due to the different mitochondrial
donors of the cybrid lines. King and Attardi [4] showed that the
variation in respiratory competence in cybrids obtained from dif-
ferent mitochondrial donors did not correlate with mtDNA copy
number. In our present study, we used, as mitochondrial donors,
primary cells from patients of very different ages. The aneuploid
nature of the parental ρ0 cells may also contribute to these differ-
ences. Therefore, we consistently compared data sets from cybrids
harbouring WT and M mtDNA from the same patient. Longi-
tudinal comparisons between all WT and all M cybrids would be
erroneous and misleading.
Lactate and pyruvate
In normal cells, glycolysis and oxidative metabolism are a con-
tinuous process, because pyruvate, the product of one pathway, is
the substrate for the other. However, when oxidative metabolism is
blocked, pyruvate and lactate are the final products of the glyco-
lytic pathway. Levels of IC lactate were significantly elevated
c© 2004 Biochemical Society
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Table 2 Lactate and pyruvate levels in cybrids harbouring mtDNA mutations
The results are expressed as the means +− S.D. for each different cell line measured in triplicate. *0.001 < P < 0.05; **P  0.001. Units: IC lactate (or pyruvate), µmol of lactate (or pyruvate)/
106 cells; EC lactate (or pyruvate), mmol of lactate (or pyruvate) in medium (from 106 cells).
IC EC
Cell line Lactate Pyruvate Lactate Pyruvate IC L/P ratio
ρ+ (143B) 15.0 +− 3 5.0 +− 1 13.52 +− 2.81 0.36 +− 0.09 3.0
ρ0 (143B206) 21.0 +− 7* 16 +− 1** 47.52 +− 4.4** 1.44 +− 0.17** 1.3
MERRF A8344G
WT 11.9 +− 4 6.8 +− 5.3 33.47 +− 8.73 0.49 +− 0.24 1.8
M 31.4 +− 18.0* 12.8 +− 9.6 54.70 +− 11.28** 0.98 +− 0.33* 2.6
MERRF T8356C
WT 6.0 +− 4.9 9.4 +− 1 20.77 +− 2.57 0.42 +− 0.09 0.6
M 27.1 +− 16.4 18.9 +− 7* 71.61 +− 24.59* 1.29 +− 0.49* 1.4
MELAS A3243G
WT 11.2 +− 3.3 11.9 +− 8 25.06 +− 9.23 0.42 +− 0.22 0.9
M 26.6 +− 13.5* 16.1 +− 6 61.81 +− 21.14* 1.08 +− 0.35* 1.7
MELAS T3271C
WT 14.2 +− 4.0 9.46 +− 4 18.30 +− 5.96 0.28 +− 0.033 1.5
M 17.5 +− 4.0 12.8 +− 5 53.14 +− 12.67* 0.92 +− 0.42* 1.4
NARP T8993C
WT 13 +− 9 6.3 +− 3 19.78 +− 6.01 0.31 +− 0.13 2.1
M 12 +− 11 8.9 +− 3 27.69 +− 6.48* 0.43 +− 0.25 1.3
NARP T8993G
WT 8.8 +− 2.3 6.75 +− 1 19.94 +− 2.24 0.33 +− 0.13 1.3
M 10.2 +− 4.3 10.5 +− 4.9 33.67 +− 12.02 0.62 +− 0.27 1.0
Deletions
CW ( 5.8 kb)
WT 14.0 +− 5.5 9.0 +− 4.3 44.39 +− 15.67 0.71 +− 0.29 1.6
M 23.7 +− 5.4* 14.1 +− 9.9 71.43 +− 22.93 1.56 +− 0.61* 1.7
FLP ( 1.9 kb)
WT 11.0 +− 6.6 10.4 +− 2.74 23.31 +− 5.31 0.46 +− 0.14 1.1
M 13.6 +− 3.4 24.5 +− 5** 72.50 +− 12.37** 1.45 +− 0.46* 0.6
in M cells harbouring the MERRF (A8344G) and the MELAS
(A3243G) mutations when compared with WT cells. In the
other M cells, including those with NARP, the MELAS T3271C
mutation, and the FLP deletion, IC lactate was only slightly
elevated or unchanged from baseline. Interestingly, in the
143B206 (ρ0) cells, which are totally glycolytic, the IC lactate was
only 40% higher than in the 143B (ρ+) cells. In cybrids harbo-
uring the CW deletion, there was only a slight increase in IC
lactate. In cells with the NARP T8993G point mutation, EC lac-
tate was increased 70%, whereas in cells with the NARP T8993C
mutation the increase was smaller (40%). The block of glucose
oxidation in MERRF (A8344G, T8356C), MELAS (A3243G,
T3271C), FLP deletion M clones, and in ρ0 controls is demon-
strated by the significantly higher EC lactate and pyruvate levels.
Not surprisingly, the enhanced lactate production seen in
cells with mtDNA mutations can be simulated in normal cells
by inhibiting mitochondrial respiration with antimycin [31,32].
Accumulation of IC lactate results in abnormally low cytosolic
pH, which, in turn, inhibits glycolysis [33]. However, cells in
culture seem to maintain IC pH by transporting IC lactate and
protons to the EC compartment, a process facilitated by MCTs
(monocarboxylate transporters). The rate of lactate transport is
determined not only by the kinetics of MCTs, but also by the
proton gradient generated by residual mitochondrial respiration
and by the volume of the EC space [34]. The large EC space
(5 ml) in our tissue culture dishes will both facilitate efflux of
lactate from the cells and dilute its EC concentration. Furthermore,
under anaerobic conditions in vitro, the lactate formed is utilized
continuously as a major respiratory fuel [35–37]. This seems to
be different from the in vivo situation in mitochondrial disease
patients, in whom lactic acidosis and high CSF (cerebrospinal
fluid) lactate are characteristic features. In patients’ tissues, cells
occupy 85% and EC space only approx. 15% of total volume
[38]. This is probably why high intracerebral lactate levels are
deleterious to the patients, whereas in cell culture EC lactate
diluted in the medium is less toxic.
IC pyruvate levels were significantly elevated in MERRF
T8356C M clones and in deleted FLP clones, whereas they were
only mildly increased in the M clones with the other mutations.
EC pyruvate levels followed the same trend as EC lactate levels,
with the exception of the NARP T8993C mutation.
Increase in both lactate and pyruvate in the EC compartment
may be deleterious to the cell, as suggested by the observation
that levels of ventricular lactate in MELAS patients correlate
with clinical severity [39]. Notably, the increase in IC and EC
lactate and pyruvate was common to all mutations (with the only
exception of NARP T8993C), perhaps because our cellular model
is predominantly glycolytic.
In our system, the IC L/P (lactate-to-pyruvate) ratio is not signi-
ficantly different in WT and M cybrids, which is in contrast with
the high L/P ratios observed in primary fibroblast or cardiomyo-
cyte cultures with respiratory chain defects [35,40–42]. This dis-
crepancy may be due to different methodologies for the measure-
ment of lactate and pyruvate or to the different cell types analysed.
Our IC lactate and pyruvate values reflect the steady-state levels
of a dynamic system, whereas in other systems lactate is measured
in cells at a fixed point in time and in the absence of glycolytic
substrates.
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Table 3 Respiratory-chain function in cybrids harbouring mtDNA mutations for each different cell line measured in triplicate
The results are expressed as the means +− S.D. *0.001 < P < 0.05; **P  0.001. Units: O2 consumption, fmol of O2 consumed/min per 106 cells; ATP synthesis and citrate synthesis, nmol/min
per mg of protein.
Cell line O2 consumption ATP synthesis Citrate synthase O2/citrate synthase ATP/citrate synthase
ρ+ (143B) 5.19 +− 0.98 35.52 +− 3.00 26.0 +− 9.07 0.218 +− 0.087 1.495 +− 0.63
ρ0 (143B206) 0.13 +− 0.36** 0.24 +− 0.07** 48.4 +− 8.20 0.007 +− 0.0001** 0.005 +− 0.001**
MERRF A8344G
WT 6.51 +− 1.93 28.86 +− 1.88 38.0 +− 10.97 0.187 +− 0.022 0.918 +− 0.043
M 1.77 +− 0.97** 0.897 +− 1.0** 51.0 +− 20.07 0.093 +− 0.033* 0.015 +− 0.011**
MERRF T8356C
WT 6.32 +− 0.71 23.815 +− 1.48 45.0 +− 5.62 0.140 +− 0.019 0.562 +− 0.04
M 0.73 +− 0.34** 0.173 +− 0.156** 57 +− 20.23 0.016 +− 0.008** 0.003 +− 0.003**
MELAS A3243G
WT 6.01 +− 0.49 36.27 +− 3.13 28.0 +− 8.76 0.236 +− 0.074 1.472 +− 0.78
M 2.76 +− 0.45** 6.150 +− 4.78* 55.0 +− 5.57 0.052 +− 0.008** 0.122 +− 0.1
MELAS T3271C
WT 8.20 +− 0.95 30.12 +− 2.10 24.0 +− 4.42 0.342 +− 0.035 1.255 +− 0.087
M 2.18 +− 0.98** 11.075 +− 0.93** 43.5 +− 2.12 0.050 +− 0.021** 0.255 +− 0.009**
NARP T8993C
WT 5.78 +− 0.86 26.59 +− 0.6 34.0 +− 15.56 0.184 +− 0.050 0.967 +− 0.32
M 4.90 +− 1.29 20.67 +− 4.04* 42.0 +− 16.97 0.111 +− 0.051* 0.540 +− 0.09
NARP T8993G
WT 2.83 +− 1.10 26.845 +− 1.10 46.0 +− 6.56 0.062 +− 0.024 0.583 +− 0.023
M 1.74 +− 0.81* 1.430 +− 1.12** 49.0 +− 4.24 0.037 +− 0.019* 0.03 +− 0.02**
Deletions
CW ( 5.8 kb)
WT 7.29 +− 2.31 14.625 +− 1.23 30.5 +− 0.71 0.239 +− 0.080 0.48 +− 0.07
M 1.39 +− 0.16* 0.82 +− 0.28** 32.0 +− 1.32 0.042 +− 0.004* 0.03 +− 0.002*
FLP ( 1.9 kb)
WT 4.65 +− 1.49 17.31 +− 1.20 32.0 +− 1.76 0.145 +− 0.047 0.708 +− 0.06
M 0.67 +− 0.31* 0.67 +− 1.20** 37.0 +− 0.98 0.018 +− 0.007* 0.018 +− 0.001**
Citrate synthesis
Since the overall rates of O2 consumption and ATP synthesis
depend on the number of mitochondria in the cell, we normalized
these values to citrate synthase activity, a nuclear-encoded
mitochondrially located enzyme of the tricarboxylic acid cycle.
The mean citrate synthase values in M cells (46 nmol/min per
mg of protein) are slightly higher than in WT cells (33 nmol/min
per mg of protein), perhaps due to compensatory mitochondrial
proliferation. When normalized to citrate synthase, the rates of O2
consumption and ATP synthesis are still significantly lower in M
cells, except for cybrids harbouring the NARP T8993C mutation
(Table 3).
O2 consumption
Rate of O2 consumption by ρ0 cells was only 2.5% of that which
occurred in 143B cells. Marked decreases in O2 consumption
were observed in the homoplasmic M cell lines compared with
the corresponding homoplasmic WT cell lines, with rates of
respiration ranging from 11% in MERRF T8356C Ms to 62%
in NARP T8993G Ms. As a notable exception, the rate of O2
consumption in cybrids harbouring the NARP T8993C mutation
was 85% of the rate in corresponding WT cybrids.
The present study confirmed our previous reports of overall
reduction of respiratory capacity in both fibroblasts and cybrids
harbouring one or another of the pathogenic mtDNA mutations
[6,8,43,44]. In addition, it reveals a close inverse correlation
between increased EC lactate levels and rates of O2 consump-
tion (Figure 1). In homoplasmic M A3243G cybrids from patients
with MIDD (maternally inherited diabetes and deafness), van den
Ouweland et al. [45] found an increased L/P ratio and a residual
O2 consumption of 21%, considerably lower than in our cells
(46%). Our results are closer to those of King et al. [6], probably
because two of our A3243G M lines and one WT cybrid line were
also used in that study [6]. On the other hand, our MELAS T3271C
M cybrids had a residual respiratory activity of 27%, contrasting
with the 62% residual activity in cybrids with the same mutation
studied by Koga et al. [7]. This discrepancy is probably due to the
low glucose concentration in our culture medium, which enhanced
the defect in mitochondrial function.
ATP synthesis
In our assay of ATP synthesis, the contribution of adenylate
kinase was reduced to insignificant levels by pre-incubating the
sample with a specific inhibitor, diadenosine pentaphosphate.
Cells were grown under controlled glycolytic conditions, as
described above, and we evaluated the oligomycin-sensitive ATP
synthase activity, which ranged between 75% and 90% of the
total. The most severe reduction of ATP synthesis was observed in
both the A8344G and the T8356C MERRF Ms, followed by the
CW and FLP deletion Ms. In these cell lines, the low rates of ATP
synthesis showed a good correlation with the reduction of re-
spiratory capacity and the increase of EC lactate and pyruvate
(Figures 1 and 2, and Tables 2 and 3). Conversely, in cybrids
with MELAS A3243G and the MELAS T3271C mutations, the
bioenergetic defects were milder and consistent with previous
studies [6,7]. Furthermore, in MELAS cybrids, residual ATP syn-
thase activities (16% for A3243G and 37% for T3271C), were
not strictly correlated with rates of O2 consumption, which
were lower in T3271C mutants than in A3243G mutants, whereas
levels of EC lactate and pyruvate were similar in the two
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mutations. The reason for this discrepancy is not clear, but
perhaps the two mutations affect the subunits of F1Fo-ATPase and
the respiratory-chain complexes in different degrees. The severe
reduction in ATP synthesis observed in NARP T8993G cybrids
(95%) does not correlate with the much milder, though signi-
ficant, reduction in ADP-dependent respiratory capacity (approx.
40%); the EC accumulation of lactate and pyruvate was also
moderate. Therefore, the most important defect observed in
NARP T8993G M cybrids was in ATP synthesis [17,19]. The
T8993G mutation changes Leu156 to Arg in the F1Fo-ATPase
subunit 6, which results in severe reduction of ATP synthesis,
but only mild impairment of ADP-stimulated respiration rate, a
different enzyme defect from that induced by oligomycin [46].
Interestingly, ATP hydrolysis in the primary fibroblasts from
which mitochondria were obtained for the cybrids used in this
study was also little affected [17]. In contrast with all other
cybrids, cell lines carrying the T8993C mutation (Leu156 to Pro)
had only slightly reduced ATP synthesis rate (78% of the control),
and no other statistically significant abnormality.
Biochemical analyses not only provide important diagnostic
clues for mitochondrial diseases, but can also shed light on patho-
genic mechanisms. However, two factors make interpretation of
published data in cybrid cells difficult. One is the lack of uniform
methods for the study of key points in energy metabolism in cells
harbouring pathogenic mtDNA mutations. The other is that most
published results were obtained with a single mutation. The avail-
ability of cybrids harbouring a representative sample of the
main pathogenic mtDNA mutations prompted us to conduct this
comparative study. Although we did observe a good correlation
among the different biochemical variables, we did not find major
differences between cells harbouring different mutations, except
for the NARP T8993C. This may be ascribed to the uniform
nuclear background (143B) of our cybrids. While the different
clinical features that are typically associated with these mtDNA
mutations remain largely unexplained, the nuclear background in
different tissues may contribute to the tissue-specific phenotypes.
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